latest news releases from the newsroom
Hydro Participates in Alunorte Alumina Expansion
OSLO, Norway, Nov. 7, 2005 (PRIMEZONE) -- Hydro will participate in the investment to increase alumina capacity at the highly competitive Alunorte refinery in Brazil. The expansion will raise annual capacity by more than 40 percent to approximately 6.5 million tonnes, making the refinery the largest and most modern in the world.
TeliaSonera Closes Deal and Acquires Chess/Sense
STOCKHOLM, Sweden, Nov. 7, 2005 (PRIMEZONE) -- TeliaSonera today announced that it had closed the deal with Vollvik Gruppen AS, 100 percent owner of Chess/Sense in Norway, to acquire 91.2 percent of the shares. The agreed price is NOK 11.03 in cash per Vollvik Gruppen AS share, equalling a total acquisition price of SEK 1,895 million (NOK 1,619 million).
Kos and Jerini Sign Exclusive Collaboration and License Agreement for Development, Marketing and Distribution of Icatibant in The United States and Canada
CRANBURY, N.J. and BERLIN, Nov. 7, 2005 (PRIMEZONE) -- Kos Life Sciences, Inc., a subsidiary of Kos Pharmaceuticals, Inc. (Nasdaq:KOSP) and Jerini U.S. Inc., a subsidiary of Jerini AG (FSE:JI4), announced today the signing of an exclusive agreement for the development, marketing and distribution of Jerini's compound, Icatibant, a potent and specific peptidomimetic bradykinin B2 receptor antagonist, in the United States and Canada. The strategic partnership includes an upfront licensing payment of EUR 12 million (approx. $15 million), along with a EUR 10 million (approx. $12 million) equity investment out of a capital increase at the higher of the weighted average of the closing price of Jerini's shares during the last four trading days, or EUR 3.20 (approx. $3.84) per share (IPO price). Undisclosed milestone payments and sales royalties are also specified in the agreement. Hereditary angioedema (HAE) is the first of several diseases for which Icatibant offers a potential treatment. The agreement outlines collaboration in the HAE area as well as other forms of angioedema, asthma, and refractory ascites in liver cirrhosis (RAIL) indications. Proof-of-concept trials have already been completed in these indications.
MorphoSys and Wacker Demonstrate High Yield Expression of Antibody Fragments
MARTINSRIED, Germany, Nov. 7, 2005 (PRIMEZONE) -- A feasibility study conducted by Wacker Biotech GmbH on behalf of MorphoSys AG (Frankfurt:MOR) (Prime Standard Segment, TecDAX) using Fab fragments, demonstrated that Wacker's E. coli secretion system can offer a far simpler and more cost-effective way of obtaining high yields of antibody fragments, which are used for research, diagnostic and therapeutic applications. Under the joint agreement, MorphoSys obtains the right to use Wacker's secretion system for antibody-fragment production in research quantities for therapeutic projects both on its own behalf and with its commercial partners.
SmallCap Sentinel: Sweet November, Historically Hot Market Month Lures Buyers
IRVINE, Calif., Nov. 5, 2005 (PRIMEZONE) -- "A recent USA Today report has highlighted November's historic benevolence to the stock market, denoting that after what is often a cautious October, that 'bullish forces emerge from hibernation and jump-start moneymaking rallies," noted SmallCap Sentinel analyst D.R. Clark. "This could well lead investors into attractive sectors such as biotech where opportunities for potential returns may lay in wait. Investors looking to salvage mediocre years in their portfolios are often more inclined to 'be aggressive' and target possible exponential return equities."
Fidelitas Management, Inc.
Fidelitas Management Changes Name to Archer Entertainment Media Communications Inc.
LOS ANGELES, Nov. 4, 2005 (PRIMEZONE) -- Fidelitas Management, Inc. (Pink Sheets:FDLM) announced that it is formally changing its name to Archer Entertainment Media Communication Incorporated, and in connection with that has applied to the NASD for a new Cusip number and trading symbol to reflect that change. In addition, the Company is proceeding with the filing of its Form 211 to become fully reporting. The company expects to cancel 60, 000,000 common restricted (rule 144) shares. FDLM recently merged with Archer.